CapForce Inc. (OTCPK: CFOR)
Health Care · Biotechnology · US
$4.00
+6.67% today · +3999900.0% 1Y
CapForce Inc. (OTCPK: CFOR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $49.54M and employs 3 people.
Over the last twelve months the share price has gained 3999900.0%, trading between 0.00 and 34.00.
Tweenvest scores CapForce Inc. across four factors: quality 51/100, value 40/100, growth 100/100. Its strongest factor is growth.
CFOR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $49.54M
- Revenue (TTM)
- $76.20M
- P/E
- 0.74
- EPS
- 5.44
- Dividend yield
- —
- Beta (5Y)
- -2,544.32
- 52-week high
- $34.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 12.38M
- Employees
- 3
- Next earnings
- —
About CapForce Inc.
CapForce Inc. is a precision medicine company dedicated to developing and commercializing sophisticated molecular microbiology solutions. Its mission is to address life-threatening infectious diseases for patients in the United States and across international markets. The company's diverse product range includes Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel diagnostic tests, and SARS CoV-2 testing kits. Beyond its product line, CapForce extends its offerings to include laboratory services, collaboration services (such as funded software arrangements), and licensing agreements. Additionally, the company provides listing sponsorship and consultancy services. Formerly known as OpGen, Inc., the entity officially changed its name to CapForce Inc. in February 2026. CapForce Inc. was established in 2001 and maintains its headquarters in Clarksburg, Maryland.
- ISIN
- US68373L5057
- Founded
- 2001
- Listed since
- May 5, 2015
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.77 | +2.07% |
Figures last refreshed Aug 18, 2026.